hVIVO PLC
LSE:HVO

Watchlist Manager
hVIVO PLC Logo
hVIVO PLC
LSE:HVO
Watchlist
Price: 22 GBX -3.93% Market Closed
Market Cap: 149.7m GBX
Have any thoughts about
hVIVO PLC?
Write Note

hVIVO PLC
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

hVIVO PLC
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
hVIVO PLC
LSE:HVO
Income from Continuing Operations
ÂŁ17.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Oxford Nanopore Technologies PLC
LSE:ONT
Income from Continuing Operations
-ÂŁ154.5m
CAGR 3-Years
-36%
CAGR 5-Years
-24%
CAGR 10-Years
N/A
Diaceutics PLC
LSE:DXRX
Income from Continuing Operations
-ÂŁ1.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genedrive PLC
LSE:GDR
Income from Continuing Operations
-ÂŁ5m
CAGR 3-Years
31%
CAGR 5-Years
10%
CAGR 10-Years
-13%
Ergomed PLC
LSE:ERGO
Income from Continuing Operations
ÂŁ15m
CAGR 3-Years
34%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C4X Discovery Holdings PLC
LSE:C4XD
Income from Continuing Operations
ÂŁ10.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

hVIVO PLC
Glance View

Market Cap
149.7m GBX
Industry
Life Sciences Tools & Services

hVIVO PLC provides pharmaceutical development services. The firm is engaged in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The company provides end-to-end early clinical development services to its client base, which includes global biopharma companies. The company offers a portfolio of approximately 10+ human challenge models to test a range of infectious and respiratory disease products, challenge agent manufacturing, specialist drug development, and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The company offers additional clinical field trial services, such as patient recruitment and clinical trial site services. The company runs challenge studies in from its Whitechapel quarantine clinic, and its QMB clinic with its specialized on-site virology and immunology laboratory.

HVO Intrinsic Value
26.83 GBX
Undervaluation 18%
Intrinsic Value
Price

See Also

What is hVIVO PLC's Income from Continuing Operations?
Income from Continuing Operations
17.4m GBP

Based on the financial report for Jun 30, 2024, hVIVO PLC's Income from Continuing Operations amounts to 17.4m GBP.

What is hVIVO PLC's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 1Y
506%

Over the last year, the Income from Continuing Operations growth was 506%.

Back to Top